Can The COVID-19 Vaccines Deliver?


AP Illustration/Peter Hamlin

There are now two promising COVID-19 vaccine candidates that have shown high degrees of efficacy in clinical trials. On November 16, 2020, biotech company Moderna, Inc. reported its vaccine showed 94.5% efficacy in early results. On November 9, Pfizer and its partner BioNTech announced it’s vaccine showed an efficacy rate above 90%. It’s worth mentioning this data has not yet been published in a peer-reviewed scientific journal, and neither vaccine has yet to receive FDA approval.


Ryan Gabrielson, reporter for ProPublica

Dr. Richard Novak, Chief of infectious disease at the University of Illinois — Chicago and the lead investigator of the clinical trials for the Moderna vaccine at UIC where they participated in Phase 3 trials


Prepared for web by Zainab Qureshi

Help shape our coverage on The 21st by joining our texting group and answering weekly questions. To join, text “TALK” to 217-803-0730 or sign up with your phone number below: